Fallopian tube cancer Trials in Cleveland, United States
Conditions / Fallopian tube cancer / Cleveland, United States
Research into Fallopian tube cancer spans multiple therapeutic approaches and trial phases.
33 total trials for this combination
Showing top 10 of 33 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | TERMINATED | PHASE2 |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT01493505 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | TERMINATED | PHASE3 |
| NCT00003380 | Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | TERMINATED | PHASE1 |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | COMPLETED | PHASE3 |
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRĪ±) Expression | COMPLETED | PHASE3 |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | COMPLETED | PHASE3 |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | TERMINATED | PHASE2 |
| NCT00245050 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | COMPLETED | PHASE3 |